← All indications
Mesothelioma, Malignant
A type of mesothelioma with a tendency to metastasize. Most tumors originate from either the PLEURA or PERITONEUM, tumors may also originate in the PERICARDIUM or testicular tissue. It is associated with ASBESTOS exposure. Somatic mutations identified in WT1, BCL10, CDKN2A, NF2, and BAP1 genes are associated with the malignancy. OMIM: 156240.
Drugs by status
Phase 3 trials (14)
Phase 2 trials (82)
- decitabine
- 68ga-nota-ae105
- abemaciclib
- pegylated arginine deiminase
- rucaparib
- axitinib
- anlotinib
- allogeneic tumor cell vaccine
- atezolizumab
- antineoplaston a10
- trabedersen
- human fibrin
- berberine
- brentuximab vedotin
- irinotecan
- crs-207
- valproic acid
- imatinib
- naltrexone
- nintedanib
- cyanocobalamin
- ramucirumab
- epirubicin
- nivolumab
- pembrolizumab
- l-alanine
- lenvatinib
- megestrol
- montanide isa 720
- amatuximab
- +52 more
Phase 1 trials (34)
- ly-3023414
- amifostine
- autologous t cells
- fulvestrant
- aldesleukin
- incomplete freund's adjuvant
- ganciclovir
- lung tumor associated antigen
- ss1(dsfv)pe38
- pa-1-stk ovarian carcinoma vaccine
- phosphatidylcholine
- sch 721015
- targomirs
- autologous dendritic cells
- primaquine
- wt-1
- cabozantinib
- re-directed fap-specific t cells
- allogeneic k562 tumor cells
- mesothelin car t cells
- midazolam
- lumefantrine
- artemether
- inbrx-109
- sg001
- apg-2449
- amt-151
- prt3645
- synkir-110
- ca9hu-1
- +4 more
Other trials (1)